Is the optimism surrounding this insulin pump maker justified?
News & Analysis: Tandem Diabetes Care
Including one or more of these three top medical-device companies in your portfolio now could be savvy.
There are some highly promising diabetes treatments entering the market that investors should know about.
The insulin pump maker once again delivered stellar quarterly results.
TNDM earnings call for the period ending September 30, 2019.
The growth stock cooled off a bit last month but has still managed to scorch the market with a 51% year-to-date gain.
These two healthcare businesses are capturing formidable growth opportunities by executing in their overlooked niches.
The medical device company is cruising past everyone's expectations -- including its own.
The dog days of summer are finally behind us (on the calendar, anyway), but these three stocks offer sizzling growth potential.
These three diabetes-oriented companies should be on your radar right now.